吉西他滨单药与联合顺铂化疗治疗中老年晚期非小细胞肺癌的疗效观察
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
吉西他滨单药与联合顺铂化疗治疗中老年晚期非小细胞肺癌的
疗效观察
黄潇;黄敏;李筱瑜;陈可和;高婷
【期刊名称】《现代肿瘤医学》
【年(卷),期】2017(025)019
【摘要】目的:评价吉西他滨联合顺铂治疗非小细胞肺癌(NSCLC)与单独使用吉西他滨的疗效与安全性.方法:140例晚期NSCLC(Ⅲb/Ⅳ期)患者随机均分为吉西他滨联合顺铂组(n=70)和单独使用吉西他滨组(n=70).联合给药组患者静脉注射吉西他滨(1 250 mg/m2,第1、8天)和顺铂(75 mg/m2,第1天);单独给药组患者静脉注射吉西他滨(1 250 mg/m2,第1、8天).每21天为一个疗程,共持续4个疗程.结果:吉西他滨与顺铂联合给药组疗效优于吉西他滨单独给药组(P<0.05).而在血细胞减少、血红蛋白减少以及恶心呕吐等不良反应上,吉西他滨单独给药组低于联合给药组,但组间比较差异无统计学意义(P>0.05).治疗后2年的随访结果也显示经吉西他滨与顺铂联合治疗的患者1年有效率及中位生存期均优于吉西他滨单独治疗组(P <0.05).结论:吉西他滨联合顺铂治疗中老年晚期非小细胞肺癌疗效确切,未明显增加不良反应,患者耐受性好,值得临床推广.%Objective:To evaluate the efficacy and safety of gemcitabine combined with cisplatin in the treatment of non-small cell lung cancer (NSCLC) and gemcitabine alone.Methods:140 patients with advanced NSCLC (stage Ⅲb/Ⅳ) were randomly d ivided into two groups:Gemcitabine plus cisplatin (n =70) and gemcitabine alone (n =70).Patients in the combined treatment group were treated with intravenous gemcitabine (1 250 mg/m2,first,eighth days)and cisplatin (75
mg/m2,first days).The patients in the treatment group were treated with intravenous gemcitabine (1 250 mg/m2,first,eighth days).Each 21 d was a course of treatment,a total of 4 courses of treatment.Results:The effect of gemcitabine and cisplatin group was significantly better than gemcitabine alone group (P <0.05).In the side effects of blood cell
reduction,hemoglobin reduction and nausea and vomiting,the gemcitabine alone group was lower than the combined treatment group,but there was no significant difference between groups (P > 0.05).The 2-year follow-up results showed that the effective rate and median survival time of patients treated with gemcitabine and cisplatin were significantly better than that of gemcitabine alone (P < 0.05).Conclusion:Gemcitabine combined with cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer is effective,without increasing side effects,the patient is well tolerated and worthy of clinical promotion.
【总页数】3页(P3079-3081)
【作者】黄潇;黄敏;李筱瑜;陈可和;高婷
【作者单位】广西壮族自治区人民医院肿瘤中心化疗二区,广西南宁530021;广西壮族自治区人民医院肿瘤中心化疗二区,广西南宁530021;广西壮族自治区人民医院肿瘤中心化疗二区,广西南宁530021;广西壮族自治区人民医院肿瘤中心化疗二区,广西南宁530021;广西壮族自治区人民医院肿瘤中心化疗二区,广西南宁530021
【正文语种】中文
【中图分类】R730.53;R734.2
【相关文献】
1.吉西他滨联合顺铂动、静脉化疗治疗晚期非小细胞肺癌的疗效观察 [J], 李艳丽;刘鹏辉;赵冠人
2.吉西他滨联合顺铂与吉西他滨单药化疗治疗晚期胰腺癌比较的Meta分析 [J], 谢德荣;梁汉霖;王羽;郭双双;杨琼;江志敏
3.吉西他滨和顺铂联合化疗对中老年晚期非小细胞肺癌的疗效观察 [J], 符琳琳;张娟
4.吉西他滨和顺铂联合化疗治疗晚期非小细胞肺癌的临床疗效观察 [J], 朱振宇
5.125I放射性粒子肺内插植联合吉西他滨+顺铂支气管动脉灌注化疗治疗中晚期非小细胞肺癌临床疗效观察 [J], 郭国华
因版权原因,仅展示原文概要,查看原文内容请购买。